CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 129 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $75,953 | +37.3% | 50,300 | +45.5% | 0.00% | – |
| Q4 2022 | $55,320 | +53.7% | 34,575 | +36.0% | 0.00% | – |
| Q3 2022 | $36,000 | -47.1% | 25,430 | -32.2% | 0.00% | – |
| Q2 2022 | $68,000 | -80.8% | 37,501 | -18.5% | 0.00% | -100.0% |
| Q1 2021 | $355,000 | -79.7% | 45,988 | -82.8% | 0.00% | -75.0% |
| Q4 2020 | $1,749,000 | +18.6% | 266,986 | +20.4% | 0.01% | +33.3% |
| Q3 2020 | $1,475,000 | -8.9% | 221,812 | +14.1% | 0.01% | -25.0% |
| Q2 2020 | $1,619,000 | -22.5% | 194,412 | -28.6% | 0.01% | -42.9% |
| Q1 2020 | $2,089,000 | -21.6% | 272,410 | -15.0% | 0.01% | +55.6% |
| Q4 2019 | $2,665,000 | +3406.6% | 320,655 | +2999.3% | 0.01% | – |
| Q3 2019 | $76,000 | -91.4% | 10,346 | -87.4% | 0.00% | -100.0% |
| Q1 2019 | $879,000 | -57.6% | 81,798 | -40.4% | 0.00% | -66.7% |
| Q4 2018 | $2,073,000 | -36.4% | 137,261 | -22.1% | 0.01% | -25.0% |
| Q3 2018 | $3,259,000 | -60.6% | 176,160 | -51.3% | 0.01% | -64.7% |
| Q2 2018 | $8,270,000 | -28.7% | 361,750 | -11.2% | 0.03% | -35.8% |
| Q1 2018 | $11,593,000 | – | 407,483 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,576,471 | $36,526,000 | 1.44% |
| Altium Capital Management LP | 273,703 | $1,793,000 | 0.67% |
| Jackson Creek Investment Advisors LLC | 80,367 | $526,000 | 0.21% |
| HARBOURVEST PARTNERS LLC | 79,193 | $519,000 | 0.20% |
| XTX MARKETS LLC | 14,169 | $93,000 | 0.19% |
| Perceptive Advisors | 2,577,043 | $16,880,000 | 0.18% |
| RTW INVESTMENTS, LP | 1,527,352 | $10,004,000 | 0.17% |
| Exane Asset Management | 30,568 | $200,220,000 | 0.14% |
| Virtus ETF Advisers LLC | 37,343 | $245,000 | 0.10% |
| Congress Park Capital LLC | 25,807 | $169,000 | 0.10% |